Balyasny Asset Management
PETX

Balyasny Asset Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Balyasny Asset Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-33,210
Closed -$141K – 2235
2018
Q2 		$141K Buy
33,210
+2,802
+9% +$14.1K ﹤0.01% 1684
2018
Q1 		$134K Buy
+30,408
New +$136K ﹤0.01% 1807

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Balyasny Asset Management's PETX Position: Q3 2018 in Review

Balyasny Asset Management sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2018, closing a stake of 33,210 shares — an estimated $141K sold.

Balyasny Asset Management first reported a position in PETX in Q1 2018 and held it in 2 quarters. The position peaked at $141K in Q2 2018. 100 funds tracked by Wall St. Rank hold PETX as of Q3 2018.

  • Balyasny Asset Management reported no remaining Aratana Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 33,210 Aratana Therapeutics, Inc. shares in Q3 2018, an estimated $141K.
  • Balyasny Asset Management first reported a position in Aratana Therapeutics, Inc. in Q1 2018 and held it in 2 quarters.
  • Balyasny Asset Management's Aratana Therapeutics, Inc. position peaked at $141K in Q2 2018.
  • 100 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2018.

Based on Balyasny Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.